Antibacterial drug discovery in the 21st century  by Bush, K
Antibacterial drug discovery in the 21st century
K. Bush
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., NJ, USA
ABSTRACT
Antibacterial research over the past 50 years has been focused on meeting medical needs caused by
infectious, life-threatening pathogens. In spite of the introduction of a variety of antibacterial agents in
multiple unrelated drug classes, resistance continues to emerge. The pharmaceutical industry must
respond to these clinical challenges by bringing forward a stream of new agents with antibacterial
activity against resistant bacteria. Although the projected growth of the anti-infective area may not be as
large as for some therapeutic areas, development advantages for these agents include their higher
predictability for success, well-deﬁned biomarkers, shorter clinical trials, and shorter duration of
therapy leading to fewer long-term safety concerns. Anti-infectives are still attractive commercially,
representing the third largest therapeutic area in terms of worldwide sales of $45 bn, with growth
predicted at least through 2010, particularly for the hospital-related products. Finally, companies that
conduct anti-infective research demonstrate their social responsibility by developing agents to treat
patients with acute and potentially fatal illnesses.
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INTRODUCTION
Antibacterial drug discovery research, accom-
panied by clinical development, has historically
been conducted by large pharmaceutical com-
panies. Although the earliest antibiotics were
ﬁrst identiﬁed in academic laboratories such as
those of Alexander Fleming (penicillin) [1] and
Selman Waksman (streptomycin) [2], pharma-
ceutical companies were responsible for success-
ful strain optimisation, compound scale-up,
formulation and clinical development activities
that allowed anti-infective drug research to gain
prominence as a viable area for corporate
investment. After the successful commercialisa-
tion of penicillin following the Second World
War, companies like Abbott, Beecham, Bristol,
Glaxo, Lederle, Lilly, Merck, Pﬁzer, Roche,
Schering and Squibb became leaders in antibi-
otic development and maintained active antibac-
terial research organisations for decades.
Although many of the former corporate leaders
have recently scaled back their efforts in this area,
antibacterial drug discovery remains an import-
ant opportunity for at least some of the pharma-
ceutical sector. In this article, four major reasons
to support the continuation of antibacterial drug
discovery are provided: medical needs based on
the continued increase in resistant pathogens,
development advantages, commercial viability,
and social factors.
MEDICAL NEED
Resistance
Soon after each antibacterial agent entered into
clinical practice, resistance was reported in at
least one bacterial pathogen (Table 1). Because the
ﬁrst antibiotics, excluding the synthetic sulfa
drugs, were all identiﬁed or derived from natural
products, resistance determinants had already
accumulated in the environments from which
these agents originated. It was only a short period
of time before selection pressures allowed these
environmental resistance determinants to become
incorporated into the pathogenic bacteria that
were being treated with the new antibiotics.
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Selection of resistant strains occurred so
quickly for some bacteria-antibiotic combinations
that clinical utility of the antibiotic was severely
diminished within a 5-year time span. The ﬁrst
documented example of the rapid selection of a
resistant population was the increase in penicillin
resistance from £8% to almost 60% in Staphylo-
coccus aureus from 1945 to 1949 (Fig. 1). In many
cases, chromosomal mutations led to class resi-
stances to other closely related agents, allowing
for the emergence of clonal strains when subjec-
ted to antibiotic pressures. Examples of chromo-
somal mutations leading to class resistances
include topoisomerase mutations selected by nal-
idixic acid and later ﬂuroroquinolones, and selec-
tion of derepressed AmpC b-lactamases by any of
a number of second and third generation cephalo-
sporins. Of perhaps even graver consequence are
the plasmid-mediated resistances, whereby a
resistant strain selected by one antibiotic can
result in resistance to other antibiotic classes due
to the presence of multiple resistance determi-
nants in the same operon. Most importantly, these
plasmids can be transferred among species,
resulting in multifactorial resistance in organisms
such as Escherichia coli, Klebsiella pneumoniae and
Pseudomonas aeruginosa.
Following the identiﬁcation of resistance to a
class or to a speciﬁc agent, the pharmaceutical
industry has responded with new generations or
new classes of drugs (Table 2). Examples of these
were the development of the ‘penicillinase-stable
penicillins’ to counteract Gram-positive b-lacta-
mases, second generation aminoglycosides to
avoid streptomycin resistance, third generation
cephalosporins to provide improved activity
against Gram-negative pathogens, the ketolide
telithromycin to avoid macrolide resistance in the
pneumococci, and linezolid in a novel class of
synthetic oxazolidinones with no cross-resistance
to any known antibiotic class. However, in all
cases, resistance has emerged to the new agents,
thus repeating the cycle (Table 1).
At this time in the history of the antibiotic
world, one might imagine that all resistance
mechanisms could be overcome by at least some
agent. Indeed, some have stated that virtually all
infections can be treated by at least a combination
of effective drugs, so it is not necessary to develop
new agents. Unfortunately, that is not the case, as
evidenced by the multidrug-resistant enteric bac-
teria, and the pan-resistant pseudomonads that
Table 1. Reported resistance to new agents following approval for clinical use
Agent for which
resistance was observed FDA approval
Resistance
reported
Mechanism of
resistance
Penicillin G 1943 1940 Penicillinase production [3]
Streptomycin 1947 1947 (Mutation in ribosomal protein S12)a [4]
Tetracycline 1952 1952 (Efﬂux)a [4]
Penicillin and tetracycline
(Neisseria gonorrhea
and enterobacteriaceae)
1943 and 1952 1976–80 Plasmid-encoded broad spectrum
b-lactamases and tetracycline efﬂux pump [5]
Methicillin (and
eventually all b-lactams
in S. aureus)
1960 1961 MecA (penicillin-binding protein 2a) [6]
Nalidixic acid 1964 1966 Topoisomerase mutations [7]
Gentamicin 1967 1969 Aminoglycoside modifying enzyme [8]
Cefotaxime 1981 1981 AmpC b-lactamase [9]
1983 Extended-spectrum b-lactamases (ESBLs) [10]
Linezolid 2000 1999 23S RNA mutation [11,12]
aAssumed to be resistance mechanism. Not identiﬁed at time of report.
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Fig. 1. Rapid increase in penicillinase production in S. au-
reus [13,14].
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are currently being treated with the toxic mem-
brane-disruptive polymyxins [15].
With the approval of the three most recent
antibacterial agents, linezolid in 2000, daptomycin
in 2003 and telithromycin in 2002–04, three new
classes of agents have been introduced into the
marketplace. However, as might be expected,
resistance has already been reported for all three
agents, thus providing an opportunity for addi-
tional agents in these classes to overcome the new
resistances identiﬁed.
Unmet needs and resistance
Why, or when, does a research organisation make
the decision to develop a new drug to counteract
resistance? A major factor must be unmet medical
need. This need is closely tied to the rapidity and
proliferation of resistance development, and the
number of other drugs that may be used for
the same therapeutic indication. One can cite
the recent ﬂurry of activity to develop
drugs to treat multidrug resistant (MDR) Gram-
positive bacteria, including MRSA (methicillin-
resistant Staphylococcus aureus) and VRE
(vancomycin-resistant enterococci). With the
increasing threats from less resistant but more
virulent community-acquired MRSA strains [16],
it should be expected that orally active agents
other than b-lactams will be of high interest. As
indicated by Livermore in this supplement [17],
other medical needs may be met with new agents
to treat infections caused by MDR pathogens such
as, Pseudomonas aeruginosa, Stenotrophomonas
maltophilia, Acinetobacter spp., Enterococcus faecium,
MDR enterobacteriaceae and MDR Mycobacterium
tuberculosis. All but MDR M. tuberculosis are
usually associated with hospital infections, thus
indicating that drugs in the hospital market will
continue to provide opportunities to meet in-
creased medical needs.
Emerging diseases
As we try to predict the future needs in infectious
diseases, there are always going to be unpredict-
able factors such as the appearance of new
diseases, or the newly recognised association of
established diseases with infectious agents.
Examples of previously unrecognised infectious
Table 2. Medical needs and drugs developed to meet them
Resistance
causing medical need
Drugs developed to counteract speciﬁc resistance
Approved drugs Drugs currently in development
Penicillinase producing
S. aureus
Penicillinase-stable penicillins: oxacillin,
methicillin, cloxacillin, dicloxacillin
BAL5788, RWJ-54428
First- and second-generation cephalosporins:
cefaclor, cephradine, cephalexin, cephalothin
Tetracycline resistance Minocycline, doxycycline Tigecycline
Gentamicin resistance Tobramycin, amikacin None
Nalidixic acid Norﬂoxacin, ciproﬂoxacin, oﬂoxacin,
levoﬂoxacin, gatiﬂoxacin, moxiﬂoxacin,
gemiﬂoxacin
Garenoxacin
TEM-1 b-lactamase in Third- and fourth-generation cephalosporins: No speciﬁed drugs
Neisseria gonorrhea followed
by increase in plasmid-mediated
penicillin resistance in
Gram-negative rods
cefoperazone, cefotaxime, ceftazidime,
ceftriaxone, cefepime
Monobactams: aztreonam
Carbapenems: imipenem
b-Lactamase inhibitors: clavulanic acid,
sulbactam, tazobactam
b-Lactam resistance caused by
production of MecA (penicillin-
binding protein 2a) in S. aureus
Quinupristin-dalfopristin, linezolid,
daptomycin
Oritavancin, dalbavancin, ramoplanin,
tigecycline, iclaprim, BAL5788,
RWJ-54428
Extended-spectrum b-lactamases
(ESBLs) in Enterobacteriaceae
Carbapenems: meropenem, ertapenem Tigecycline, doripenem
Vancomycin resistance
in enterococci
Quinupristin-dalfopristin, linezolid,
daptomycin
Oritavancin, ramoplanin, tigecycline
Macrolide-resistant streptococci Telithromycin No speciﬁed drugs
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diseases are Legionnaire’s disease that was found
to be associated with Legionella pneumophila [18],
and multiple viral diseases such as ebola, AIDS,
hepatitis C and SARS. Diseases described before
they were known to be caused by infectious
agents include cat scratch disease caused by
Bartonella henselae [19], and gastric ulcers caused
by Helicobacter pylori [20]. In addition, diseases
that were once thought to be under control by
existing therapies may re-emerge, such as cholera,
dengue and pertussis.
As with the case of H. pylori and ulcers, there is
a great deal of curiosity in the infectious disease
community as to possible anti-infective links with
other chronic diseases such as cardiovascular or
neurological disorders. Clinical studies that have
studied the effect of azithromycin therapy on the
treatment of atherosclerosis have been equivocal,
in part, because it has not been convincingly
determined whether the Chlamydia pneumoniae in
arterial plaque is the causative agent or present as
an innocent bystander in a favourable environ-
mental niche [21,22]. However, if a causal associ-
ation is proven, a large commercial opportunity
awaits the company that can present data from a
positive trial with a new antichlamydial agent.
Likewise, hints of associations between C. pneu-
moniae and Alzheimer’s disease or asthma [23,24]
suggest that there may be additional chronic
illnesses that may ultimately beneﬁt from anti-
bacterial therapy. If these opportunities are devel-
oped in the future, this will provide another set of
pressures to increase antibacterial resistance, and
will provide incentives for companies to identify
new organism-speciﬁc agents.
Finally, there is now the threat of epidemic
outbreaks of resistant organisms in attacks of
bioterrorism. Although the mail attacks of anthrax
in the USA were fortunately conducted with a
highly susceptible Bacillus anthracis strain in 2001
[25], it is now well established that antibiotic-
resistant strains can be readily selected in vitro [26],
thus leading to the possibility of more resistant
strains appearing in the future. Because inhala-
tional anthrax is most frequently a fatal disease
due to rapid toxin production, opportunities are
available to approach this disease state more
creatively, with the development of drugs to attack
the toxin itself, in addition to the use of classical
antibacterial agents to eradicate the bacteria [27].
And, development of safe and effective vaccines is
still an option that is frequently ignored.
Dosing advantages
In addition to a medical need to treat a resistant
infection, there can be less obvious medical
advantages offered by new agents. Frequency of
dosing is one area in which new drugs have made
an important difference. An early example was
the replacement of ampicillin by amoxicillin
because the dosing regimen changed from four
times a day to three times a day. Ceftriaxone with
once-a-day dosing became a more highly used
drug than cefotaxime dosed three times a day, in
spite of the fact that cefotaxime was introduced to
the market ﬁrst and had an interchangeable
spectrum of activity with ceftriaxone. Also,
levoﬂoxacin with once-a-day dosing replaced
twice-a-day ciproﬂoxacin as the leading hospital
ﬂuoroquinolone. These changes in dosing regi-
mens can result in higher patient compliance,
especially in the outpatient population where
once-a-day dosing has become the standard of
care. In the hospital setting, reduced dosing
frequencies can lead to lower medical costs due
to the resources involved in delivering parenteral
agents. There also are advantages offered by
providing both oral and parenteral agents so that
hospitalised patients can be transferred from
intravenous (i.v.) therapy to oral therapy on the
same drug, and subsequently released from the
hospital earlier. These attributes are shared by
many of the ﬂuoroquinolones and by linezolid
where both oral and i.v. forms are available.
Safety improvements
Improvement in safety can also provide an oppor-
tunity for development of a second- or third-in-
class agent. Although some adverse events are
inherently associated with speciﬁc antibiotic clas-
ses, the degree to which these manifest can vary
greatly.Nephrotoxicitywith cephalosporins canbe
a major problem, with drugs like cephaloridine
removed from the market because of their renal
toxicity. However, the plethora of ‘cephawhat-
chamacallums’ in the 1980s [28] can be attributed to
the fact that the newer cephalosporins exhibited
good safety proﬁles with minimal nephrotoxicity
when normal doses were given. Fluoroquinolones
generally exhibit binding to the hERG ion channel
as a class, but the IC50 values for binding in the
patch clamp assay can vary by as much as two
orders ofmagnitude, from18 lM for sparﬂoxacin to
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1420 lM for oﬂoxacin [29]. Thus, theremaybe room
to improve safety proﬁles and drug–drug interac-
tions for currently existing antibacterial agents
such as linezolid with its reversible monoamine
oxidase inhibition [30] and telithromycin with its
reversible cytochrome P450 interactions [31].
DEVELOPMENT FACTORS
Attractive development opportunities
Development of anti-infective agents offers cer-
tain attractions not seen with some other thera-
peutic areas. Based on historical data through the
end of 1999, the probability of an investigational
anti-infective agent entering the market was
higher than for agents in other therapeutic areas,
as shown in Fig. 2 [32]. This advantage is
especially notable when success was measured
from the ﬁrst human dose (Phase 1), ﬁrst patient
dose (Phase 2) or ﬁrst pivotal dose (Phase 3) when
anti-infective agents were compared with cardio-
vascular, oncology or central nervous system
(CNS) drugs [33].
Other historical data indicate that FDA appro-
val times were faster for anti-infective agents
compared with drugs in the other therapeutic
areas. As seen in Table 3, during each develop-
ment phase, anti-infectives had the shortest resi-
dency time compared with cardiovascular,
NSAIDs and CNS agents [34]. In addition, the
capitalised clinical costs per approved NCE were
lowest for anti-infective drugs compared with the
other therapeutic areas [34].
Several possible reasons may be cited for the
development advantages for anti-infective drugs.
First, the drug targets are clearly delineated, with
well-established in vitro testing to show that drugs
can get to their targets and have the desired
therapeutic effect, i.e., killing of the micro-organ-
ism. Second, good predictive in vivo efﬁcacy mod-
els have been established for a variety of infections
caused by speciﬁc target organisms, leading to
reassurance that clinical trials have a high probab-
ility of success. Third, there are clearly deﬁned
biomarkers to allow for monitoring of patients in
clinical trials. Fourth, the use of pharmacodynam-
ics to predict efﬁcacy, optimal doses, and the
potential for resistance selection has become a
sophisticated art in the anti-infective area. And
ﬁfth, safety issues, especially for hospital-admin-
istered drugs, tend to be less than for drugs that are
prescribed for chronic illnesseswhere a patientwill
take a drug for the rest of his life. Finally, for
community drugswith decreased dosing regimens
of 3–5 days, long-term safety and follow-up stud-
ies lasting for years are generally not required,
thereby leading to shorter clinical trials.
Development role for large companies
Large pharmaceutical companies must continue to
play amajor role in the discovery anddevelopment
of new anti-infective agents. Companies with
active antibacterial research and development
programmes currently have the resources and
talent to be able to take a drug from the conception
stage through to full FDA approval. The basic
research scientists in these groups have established
resources in terms of ﬁnancial support and facilit-
ies, and have the experience and commitment to
follow a drug from identiﬁcation through to study-
ing clinical isolates for mechanisms of resistance.
Development scientists have expertise to run the
toxicology and drug metabolism studies, to scale-
up compounds under GMP conditions for clinical
supplies, and to formulate the agents in pharma-
cologically acceptable forms. Clinical scientists
have experience in running clinical trials, with
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Fig. 2. Success rates according to therapeutic class for self-
originated NCEs that had INDs ﬁrst ﬁled from 1981 to 1992
[32].
Table 3. Average months in each development phase
according to therapeutic area [34]
Average number of months
Therapeutic Area
Phase
I
Phase
II
Phase
II NDA
Anti-infectives 11 14 36 24
Cardiovascular 17 35 39 30
NSAID 21 23 55 39
Neuropharmacological 14 24 41 43
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appropriate contacts and clinical sites in place for
future studies. And, regulatory groups have
experience with the various regulatory agencies
so that proper documentation and records are
maintained and ﬁled throughout the development
process. It is imperative that companies with these
sets of experienced investigatorsmaintain a critical
mass before this expertise is ﬁltered away into
other therapeutic areas.
Because many of the same functions are in
place for all therapeutic areas, a large company
can capitalise on the knowledge from other
groups. Shared resources such as scale-up chem-
istry, formulations, toxicology, metabolism and
regulatory groups can work on compounds from
any therapeutic area, so dedicated personnel are
not lying in wait for the next compound to enter
development. Also, because the return on invest-
ment may be perceived to be lower for anti-
infective drugs [35], the ability to balance a
portfolio with drugs from multiple therapeutic
classes means that large companies can afford to
stay in less lucrative areas of research such as
antibacterial development.
COMMERCIAL VIABILITY
Worldwide sales
In addition to the scientiﬁc and developmental
opportunities in the anti-infectives area, it is still
necessary to show that there is a commercial
rationale for staying in this area. When worldwide
pharmaceutical sales are broken down by thera-
peutic area, anti-infective agents rank third,
behind cardiovascular and CNS drugs (Table 4)
[36,37]. The anti-infective market with US $45 bn
in sales is further divided into antibacterial,
antifungal and antiviral areas (Table 5), with
antibacterial sales providing almost two-thirds of
the total revenue [36]. Although other areas of
anti-infective drugs have been projected to grow
faster than antibacterial agents for the next few
years, all sectors show a positive growth rate, with
an overall growth of 10% for all anti-infectives.
Interestingly, when the increase in sales is
computed in terms of actual dollars, the largest
absolute increase in growth is projected for the
antibacterial group (Table 5). This total represents
an increase of $1.7 bn per year. Although com-
panies like to boast about the number of billion-
dollar drugs in their portfolio, one does not need
to introduce a billion-dollar drug every year to be
proﬁtable. If a mix of parenteral agents is sold by
a single company, sales exceeding $1 bn can be
achieved by using the same hospital sales force to
market three drugs with sales of $400 m or less.
Over the next 5 years growth in the critical care
antibacterial market is projected to increase con-
sistently, based on the increase in antibiotic sales
from 1999 to 2002 [38]. This growth can be directly
related to the increase in serious infections caused
by problem Gram-negative pathogens that are
invading the intensive care units of hospitals. It is
interesting to note that sales appear to grow for
quinolones, carbapenems and new agents, but are
Table 4. Worldwide pharmaceutical sales of agents in
various therapeutic areas including prescription and over-
the-counter sales
Therapeutic Area
2002
Sales
($bn)a
Total
Sales
(%)a
Population
sharesb
Cardiovascular 67 16.8 23.2
CNS 64 16.0 17.9
Anti-infectives 45 11.2 12.8
Gastrointestinal 35 8.7 2.1
Respiratory 33 8.2 6.0
Endocrinology ⁄
metabolic
32 8.0 7.0
Oncology ⁄ immunology 27 6.7 12.4
Rheumatology ⁄
musculoskeletal
23 5.7 NDc
Haematology 22 5.5 ND
Miscellaneous 53 13.2 18.3
Total 401 (100) (100)
aIMS Health World Review.
bData through 2000 [37].
cNo data provided.
Table 5. Worldwide anti-infective market sales and pro-
jected growth [36]
Anti-infective
area
Sales
in $bn
(% Total)
4 years
CAGRa
Annual
growth
in sales ($bn)
Antibacterials 27.9 (62%) +6% 1.7
HIV antivirals 5.4 (12%) +22% 1.2
Non-HIV antivirals 2.7 (6%) +22% 0.6
Antifungals 3.2 (7%) +10% 0.3
Sera, vaccines and
immunoglobulins
5.9 (13%) +14% 0.8
Total 45 (100%) +10% (4.5)b
aCompounded annual growth rate based on data from
1998 to 2002.
bValues do not add up to $4.5 bn due to rounding.
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projected to decrease or remain steady for the
penicillins and cephalosporins. Thismay reﬂect the
increase in generic agents available in those areas,
or the increasing resistance to these agents among
Gram-negative pathogens.
CORPORATE RESPONSIBILITY
Social commitment
Every pharmaceutical company has established a
position of social and corporate responsibility to
meet the medical needs of its customers. A survey
of corporate websites has identiﬁed statements
of corporate responsibility for virtually every
pharmaceutical company in the Western world.
These statements, although unique to a speciﬁc
company, all include many similar expressions
such as ‘responsibility’, ‘commitment’, ‘commu-
nity’, ‘values’ and ‘vision’. However, this corpor-
ate responsibility extends beyond internet
webpages. Examples of this social commitment
include the corporate donations or price-lowering
for ivermectin to treat river blindness (Merck), for
miconazole for AIDS-affected individuals (Tibo-
tec), and for anti-HIV drugs (GSK) to African
populations that cannot afford to pay full price for
these agents. Large companies such as AstraZen-
eca and Johnson & Johnson have demonstrated a
social commitment to less proﬁtable research by
working on drugs to treat multidrug resistant
tuberculosis.
All companies exemplify a concern for the
welfare of their customers who are constantly
looking for new drugs and new treatments to
improve their quality of life. However, in the area
of anti-infective research, the goal is perhaps one
of even greater commitment. The agents that have
been developed in the past, and that are being
developed for future needs, are not drugs that
improve the ‘quality of life’, but are agents that
frequently treat acute, life-threatening diseases.
CONCLUSIONS
We need to remember that the antibiotic era
began only about 60 years ago at a time when a
strep throat could mean a death sentence.
Although we have been proliﬁc in the past by
developing new antibiotics rapidly, those days
are behind us, as so clearly outlined by a number
of recent reports, including those from Projan and
Shlaes [39] and from Powers [40] in this supple-
ment. With the increasing multidrug resistance
that threatens our entire armamentarium of anti-
biotics, it is imperative that new agents continue
to be developed. And, perhaps more importantly,
it is critical that large pharmaceutical companies
continue to fund basic research to identify the
new agents that will be able to circumvent newly
emerging mechanisms. There are sound scientiﬁc,
medical, developmental and commercial reasons
for companies to remain in the anti-infective
therapeutic area. Although we will always live
in a world coinhabited by antibiotic-resistant
bacteria, we have a social commitment to devise
new approaches to contain them before it is too
late.
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